Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H, WKN: A3EKSZ) has taken a significant step toward expanding its oncology portfolio by entering into a non-binding letter of intent (LOI) with Ifowonco Informatics Incorporated. The LOI is the initial phase in negotiating a definitive agreement that would grant Onco an exclusive option on Ifowonco’s proprietary small-molecule inhibitor program targeting lymphocyte-activation gene 3 (LAG-3). This move could substantially enhance the company's position in the competitive field of cancer immunotherapy.
The proposed collaboration is designed to combine Ifowonco’s oral small-molecule immune checkpoint technology with Onco-Innovations’ expertise in DNA damage response (DDR) therapeutics, translational oncology, and clinical development. The companies believe that combining DDR inhibition with LAG-3 blockade could potentially enhance anti-tumour immune responses across multiple solid tumour indications. This synergistic approach is particularly noteworthy because LAG-3 is an immune checkpoint receptor that suppresses T-cell activity, and inhibiting it has shown promise in reactivating the immune system against cancer cells.
Ifowonco’s program focuses on developing orally available small-molecule LAG-3 inhibitors, a distinct advantage over currently approved LAG-3 therapies, which are administered intravenously as monoclonal antibodies. Oral administration could offer greater convenience, potentially improving patient compliance and enabling more flexible dosing regimens. The companies intend to evaluate the LAG-3 program independently and, where supported by preclinical findings, explore its potential use alongside DDR-based therapeutic approaches, including Onco-Innovations’ ONC010 program.
Thomas O’Shaughnessy, CEO of Onco-Innovations, emphasized the strategic importance of the potential agreement, stating that it could position the company “at the intersection of precision oncology and next-generation cancer immunotherapy.” This aligns with the company’s mission to pursue the prevention and treatment of cancer through pioneering research and innovative solutions. Onco-Innovations has already secured an exclusive worldwide license to patented technology targeting solid tumours, and this new initiative could further diversify its pipeline.
The announcement underscores a broader trend in oncology towards combining different therapeutic modalities to improve treatment outcomes. By integrating DDR inhibitors, which exploit cancer cells’ defective DNA repair mechanisms, with immune checkpoint inhibitors like LAG-3 blockers, the hope is to create a more robust anti-tumour response. This could be particularly beneficial for patients with solid tumours that have not responded well to existing immunotherapies.
For more details on this development, the full press release can be accessed at https://ibn.fm/E63Ne. Investors and stakeholders can also stay updated with the latest news and updates relating to ONNVF in the company’s newsroom at https://ibn.fm/ONNVF.
As Onco-Innovations advances this potential collaboration, the biotechnology community will be watching closely to see whether the oral LAG-3 inhibitor can deliver on its promise and potentially lead to new treatment options for cancer patients. The successful execution of this agreement could mark a significant milestone for the company and the field of cancer immunotherapy.
